A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
Public ClinicalTrials.gov record NCT01632228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma. Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab. Study treatment will continue until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study identification
- NCT ID
- NCT01632228
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2012 (Actual)
- Primary completion
- Jan 21, 2016 (Actual)
- Completion
- Jan 21, 2016 (Actual)
- Last update posted
- Feb 5, 2018
2012 – 2016
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama At Birmingham; Neuro-Oncology | Birmingham | Alabama | 35294 | — |
| Cedars Sinai Medical Center; Neurosurgery | Los Angeles | California | 90048 | — |
| UCLA | Los Angeles | California | 90095 | — |
| USCF - Neurosurgery | San Francisco | California | 94143 | — |
| Stanford Comprehensive Cancer Center | Stanford | California | 94305 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Florida Cancer Specialists - Englewood | Englewood | Florida | 34223 | — |
| Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building) | St. Petersburg | Florida | 33705 | — |
| Moffitt Cancer Center | Tampa | Florida | 33647 | — |
| North Western Univ; Neurology | Chicago | Illinois | 60611 | — |
| Northshore University Health System; Cardiology | Evanston | Illinois | 60201 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Hatton Research Institutes | Cincinnati | Ohio | 45220 | — |
| Sarah Cannon Cancer Center - Tennessee Oncology, Pllc | Nashville | Tennessee | 37203 | — |
| Baylor Research Inst. | Dallas | Texas | 75246 | — |
| University of Virgina | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
| Seattle Cancer Care Alliance; Investigational Drug Service | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01632228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2018 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01632228 live on ClinicalTrials.gov.